Navigation Links
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Date:10/6/2008

nal (10%)

-- The most frequent adverse events seen in patients with metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater than or equal to 50%) were acneform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%). The most common grade 3/4 adverse events (greater than or equal to 10%) included: diarrhea (22%), leukopenia (17%), asthenia/malaise (16%), and acneform rash (14%)

Important Safety Information for ALIMTA

ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is a treatment for Malignant Pleural Mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anti-cancer medicine (chemotherapy) when surgery is not an option.

Myelosuppression is usually the dose-limiting toxicity with ALIMTA therapy.

ALIMTA may not be appropriate for some patients. If you are allergic to ALIMTA, tell your doctor because you should not receive it. If you think you are pregnant, are planning to be pregnant, or are nursing, please tell your healthcare team. ALIMTA may harm your unborn or nursing baby. Your physician may advise you to use effective contraception (birth control) to prevent pregnancy while you are being treated with ALIMTA.

If you have liver or kidney problems, be sure to tell your doctor. Your dose of ALIMTA may have to be changed, or ALIM
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
2. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
3. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
4. Amylin and Lilly Set Date and Time for Conference Call
5. Lilly Announces Completion of SGX Acquisition
6. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
7. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
8. Lilly Reports Solid Second-Quarter Results
9. Lilly to Acquire SGX Pharmaceuticals
10. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
11. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index ... , in particular, drug/device combinations. The current system received a score of 0 (range ... Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Inc. ("Chromos" or the "Company"; TSX: CHR) today provided ... of Directors of Chromos today announced that Mr. Alistair,Duncan ... effective,immediately. He has also resigned as a Director of ... President and CEO since 1998., Mr. Roger Flowerdew, ...
... Education and Finger Health in Diabetes Management, ... 16 Pelikan,Technologies Inc., a leading developer ... Eli Lilly and Company today announced the,signing ... terms of the,co-promotion agreement, the companies will ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan,Melcher ... Hospital in Leeds,U.K. published the results of their ... Therapy. The paper is entitled "Inflammatory Tumour Cell ... The investigators showed that reovirus effectively kills ...
Cached Biology Technology:Chromos provides shareholder update 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 3Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 4Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... here have used a new microscopic, three-dimensional scaffolding to coax ... then to function identical to how fat cells naturally do ... fat cells, or adipocytes, in the laboratory, those cells never ... tissue. They failed to produce the genetic and biologic components ...
... have discovered a potential new drug that inhibits destructive ... all cancers. The scientists showed they could block the ... compound, called cysmethynil. , Their finding, reported in the ... Academy of Sciences, is the first step toward developing ...
... To understand the formation of the brain-clogging deposits ... diseases, Duke University chemists have figured out how ... blocks of the deposits. , Their aim is ... toxic protein called amyloid plaque. Such basic understanding, ...
Cached Biology News:Tiny scaffolding allows stem cells to become working fat cells 2Tiny scaffolding allows stem cells to become working fat cells 3Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimer's, Parkinson's Disease 2
... HEEBO (Human Exonic Evidence Based Oligonucleotide) Genome ... Oligonucleotide ) Genome Set contain a collection ... from constitutively expressed exons, allowing interrogation of ... leading researchers at Stanford University and UCSF, ...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
...
Biology Products: